

October 28, 2026



Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter ended September 30, 2026, after the financial markets close on Wednesday, November 4, 2026.

Wednesday, November 4th @ 4:30 p.m. ET

Domestic:

1-877-704-4453

International:

1-201-389-0920

Conference ID:

13762560

Webcast:

[Link](#)

A live webcast of the conference call may also be found on the [News & Events](#) page in the Investors section of the Mineralys Therapeutics website.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit <https://mineralystx.com>. Follow Mineralys on [LinkedIn](#), [X](#) and [Bluesky](#).

Contact:

Investor Relations

investorrelations@mineralystx.com

Media Relations

Melyssa Weible

Elixir Health Public Relations

Email: mweible@elixirhealthpr.com



Source: Mineralys Therapeutics, Inc.